There is a general consensus that substantial heterogeneity underlies the neurobiology in autism spectrum disorder (ASD). As such, it has become increasingly clear that a dissection of variation at the molecular-, cellular-, and system-level domains is a prerequisite for identifying biomarkers and developing more targeted therapeutic strategies in ASD. Advances in neuroimaging approaches to characterizing atypical brain patterns have recently motivated their application as viable tools to delineate more homogenous ASD subgroups at the level of brain structure and function -i.e., neurosubtyping. This review assesses and critically discusses the current datadriven neurosubtyping in ASD. It breaks this pursuit into key methodological steps: the selection of diagnostic samples, neuroimaging features, algorithm and validation approaches. For each step, we appraise the current literature in terms of progress, as well as remaining challenges and potential solutions. Convergence across findings is discussed and biological implications are highlighted. Although preliminary and with limited methodological overlap, results from this literature illustrate the feasibility of neurosubtyping. Across studies, there is general agreement that distinct neurosubtypes exist, but the exact number and their definitions vary depending on the specific features and approach utilized in a given study. Results also suggest the utility of subtypes in predicting symptom severity and diagnostic labels above and beyond group-average comparison designs. This review concludes with a discussion of future avenues towards a comprehensive understanding of the mechanisms underlying ASD heterogeneity.